Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Association between angiotensin receptor blockers and better cognitive outcome: urgent need for a randomized trial.

Oprisiu R, Fournier A, Achard JM, Black SE, Serot JM, Godefroy O.

JAMA Neurol. 2013 Mar 1;70(3):413-4. doi: 10.1001/jamaneurol.2013.1804. No abstract available.

PMID:
23478839
2.

Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

Ong HT.

J Am Board Fam Med. 2009 Nov-Dec;22(6):686-97. doi: 10.3122/jabfm.2009.06.090094. Review.

3.

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N.

Expert Rev Neurother. 2009 Sep;9(9):1413-31. doi: 10.1586/ern.09.89. Review.

PMID:
19769454
4.

Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population.

Hajjar I, Catoe H, Sixta S, Boland R, Johnson D, Hirth V, Wieland D, Eleazer P.

J Gerontol A Biol Sci Med Sci. 2005 Jan;60(1):67-73.

PMID:
15741285
5.

Vascular benefits of angiotensin receptor blockers.

Voors AA.

Expert Opin Investig Drugs. 2007 Jul;16(7):987-97. Review.

PMID:
17594184
6.

Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.

Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators..

J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38.

PMID:
16645357
7.

Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Taylor AA, Siragy H, Nesbitt S.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):677-86. doi: 10.1111/j.1751-7176.2011.00518.x. Review.

8.

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.

Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005.

PMID:
22770926
9.

Are there differences among angiotensin receptor blockers?

Zusman RM.

Am J Hypertens. 1999 Dec;12(12 Pt 3):231S-235S. Review.

PMID:
10619576
10.
11.

Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.

Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.

J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.

PMID:
18550998
12.

Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.

Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA; VATTC Trial..

J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32. doi: 10.1093/jnci/djn262.

PMID:
18728281
14.
15.

Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?

Volpe M.

QJM. 2012 Jan;105(1):11-27. doi: 10.1093/qjmed/hcr190. Review.

PMID:
22011630
16.

How to use marginal structural models in randomized trials to estimate the natural direct and indirect effects of therapies mediated by causal intermediates.

Oba K, Sato T, Ogihara T, Saruta T, Nakao K.

Clin Trials. 2011 Jun;8(3):277-87. doi: 10.1177/1740774511402526. Erratum in: Clin Trials. 2011;8(5):680.

PMID:
21730076
18.

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?

Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G.

Curr Vasc Pharmacol. 2010 Nov;8(6):742-6.

PMID:
20626343
19.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.

Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, Hu YM, Zhao SQ, Wang M, Zhang WY, Liu XR, Wu T, Arkin A, Zhang TJ.

Eur J Clin Invest. 2011 Jul;41(7):719-33. doi: 10.1111/j.1365-2362.2010.02460.x. Review.

PMID:
21250983
20.

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.

Dowlatshahi D, Hill MD.

Expert Rev Cardiovasc Ther. 2009 May;7(5):459-64. doi: 10.1586/erc.09.3.

PMID:
19419253

Supplemental Content

Support Center